London
· Delayed Price · Currency is GBP · Price in EUR Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of GBP 123.61 million. The enterprise value is 76.00 million.
| Market Cap | 123.61M |
| Enterprise Value | 76.00M |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.01% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 34.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.63 |
| EV / Sales | 2.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.88 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 1.23.
| Current Ratio | 2.92 |
| Quick Ratio | 2.76 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.93 |
| Interest Coverage | -62.63 |
Financial Efficiency
Return on equity (ROE) is -78.59% and return on invested capital (ROIC) is -29.62%.
| Return on Equity (ROE) | -78.59% |
| Return on Assets (ROA) | -13.76% |
| Return on Capital (ROIC) | -29.62% |
| Revenue Per Employee | 170,513 |
| Profits Per Employee | -171,845 |
| Employee Count | 179 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.85% in the last 52 weeks. The beta is 0.87, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -27.85% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 2.00 |
| Relative Strength Index (RSI) | 48.98 |
| Average Volume (20 Days) | 2,079 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innate Pharma had revenue of GBP 28.65 million and -28.87 million in losses. Loss per share was -0.36.
| Revenue | 28.65M |
| Gross Profit | -16.84M |
| Operating Income | -32.71M |
| Pretax Income | -28.87M |
| Net Income | -28.87M |
| EBITDA | -30.49M |
| EBIT | -32.71M |
| Loss Per Share | -0.36 |
Balance Sheet
The company has 77.83 million in cash and 30.10 million in debt, giving a net cash position of 47.73 million.
| Cash & Cash Equivalents | 77.83M |
| Total Debt | 30.10M |
| Net Cash | 47.73M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 24.41M |
| Book Value Per Share | 0.30 |
| Working Capital | 62.20M |
Cash Flow
In the last 12 months, operating cash flow was -15.31 million and capital expenditures -275,541, giving a free cash flow of -15.58 million.
| Operating Cash Flow | -15.31M |
| Capital Expenditures | -275,541 |
| Free Cash Flow | -15.58M |
| FCF Per Share | n/a |
Margins
Gross margin is -58.77%, with operating and profit margins of -114.19% and -100.78%.
| Gross Margin | -58.77% |
| Operating Margin | -114.19% |
| Pretax Margin | -100.78% |
| Profit Margin | -100.78% |
| EBITDA Margin | -106.43% |
| EBIT Margin | -114.19% |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.01% |
| Shareholder Yield | -1.01% |
| Earnings Yield | -23.36% |
| FCF Yield | -12.61% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -2.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.42 |
| Piotroski F-Score | n/a |